Anonymous8 days ago
Daraxonrasib, an oral RAS inhibitor developed by Revolution Medicines, nearly doubled median overall survival in previously treated metastatic pancreatic cancer patients in the Phase 3 RASolute 302 trial. But the drug remains unapproved, available only through expanded access, and out of reach for many patients — particularly those treated at community oncology centers that lack the molecular testing infrastructure, specialist knowledge, or administrative capacity to navigate the application process.